Market narrative

Read the headlines around the signals.

Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.

Latest feeds.newsfilecorp.com · about 20 hours ago

Metatek Awarded Department of Energy Contract in the Philippines

Calgary, Alberta--(Newsfile Corp. - August 4, 2026) - Metatek Group Ltd. (TSX: MTEK) ("Metatek" or the "Company"), the exclusive global provider

Press releases

More recent coverage

Page 53
TTNDY businesswire.com · about 20 hours ago

Techtronic Industries Delivers Strong First Half Performance

HONG KONG--(BUSINESS WIRE)--Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of.

TDG prnewswire.com · about 20 hours ago

TransDigm Group Reports Fiscal 2026 Third Quarter Results

CLEVELAND, Aug. 4, 2026 /PRNewswire/ -- TransDigm Group Incorporated (NYSE: TDG), a leading global designer, producer and supplier of highly engineered aircraft components, today reported results for the third quarter ended June 27, 2026. Third quarter highlights include: Net sales of $2,741 million, up 23% from $2,237 million in the prior year's quarter; Net income of $540 million, up 10% from the prior year's quarter; Earnings per share of $9.39, up 11% from the prior year's quarter; EBITDA As Defined of $1,447 million, up 19% from $1,217 million in the prior year's quarter; EBITDA As Defined margin of 52.8%; Adjusted earnings per share of $10.87, up 13% from $9.60 in the prior year's quarter; and Upward revision to fiscal 2026 financial guidance.

MGA newsfilecorp.com · about 20 hours ago

STLLR Gold Intersects 3.11 g/t Au over 15.70 m at the Jonpol Deposit of the Tower Gold Project and Announces Board Change

Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - STLLR Gold Inc. (TSX: STLR) (OTCQX: STLRF) (FSE: O9D) ("STLLR" or the "Company") reports additional assay results from its 2026 drilling program at the Jonpol Deposit ("Jonpol") at the Garrison Property of the Tower Gold Project ("Tower" or the "Project") in the Timmins Mining Camp in Ontario, Canada. Table 1: 2026 Jonpol Deposit Drilling Highlights: Zone Hole ID Assay Result Jonpol MGA26-276 3.11 g/t Au (2.00 g/t Au, cut) over 15.70 m (9.57 m TT) (including 5.15 g/t Au over 1.00 m (0.61 m TT) & 49.20 g/t Au (25.00 g/t Au, cut) over 0.72 m (0.44 m TT) Jonpol MGA26-277 1.44 g/t Au over 33.77 m (12.00 m TT) (including 2.36 g/t Au over 9.69 m (3.44 m TT) Jonpol MGA26-275 2.41 g/t Au over 16.00 m (10.49 m TT)(including 4.71 g/t Au over 1.00 m (0.65 m TT)   "g/t Au" = grams per tonne gold; "m" = metres; "TT" = True Thickness "Our latest drilling continues to deliver high-grade, near-surface gold intersections, demonstrating the exceptional potential of the Jonpol Deposit," said Keyvan Salehi, P.Eng.

ALHC newsfilecorp.com · about 20 hours ago

Kaplan Fox Encourages Alignment Healthcare, Inc. (ALHC) Investors to Contact the Firm Regarding a Securities Investigation

New York, New York--(Newsfile Corp. - August 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or the "Company") (NASDAQ: ALHC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Alignment Healthcare investor and have suffered losses, or if you have information that could assist in the Alignment Healthcare investigation, you may CLICK HERE to contact us.

PBK prnewswire.com · about 20 hours ago

BESS 903 Project Passes Major Permitting Milestone, Advancing PowerBank's Ontario Battery Storage Pipeline

PowerBank's Second Battery Energy Storage System has secured Official Plan Amendment and Zoning Bylaw Amendment approvals TORONTO, Aug. 4, 2026 /PRNewswire/ -- PowerBank Corporation (Nasdaq: PBK) (Cboe CA: PBK) (FSE: 103) ("PowerBank" or the "Company"), a leader in independent energy development and asset ownership in North America, is pleased to announce that on July 21, 2026, the 903 BESS project (the "Project") secured Official Plan Amendment and Zoning Bylaw Amendment approvals, representing a significant regulatory milestone. These approvals conclude the longest and most complex phase of the permitting process, which included extensive public consultation.

XMTR globenewswire.com · about 20 hours ago

Xometry Reports Record Second Quarter 2026 Results

NORTH BETHESDA, Md., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the second quarter ended June 30, 2026.

ISOU prnewswire.com · about 20 hours ago

DISA Technologies Launches DISA Uranium Corporation, a New American Uranium Recovery and Production Platform

DISA Uranium holds the only U.S. Nuclear Regulatory Commission license authorizing the remediation and recovery of abandoned uranium mine waste across multiple sites, and pairs that pipeline with a newly acquired  conventional resource base in Utah from IsoEnergy Ltd. This will underpin the company's plans to build the first new U.S. uranium recovery and processing facility in more than four decades.

IVVD globenewswire.com · about 20 hours ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an aggregate of 277,500 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

RYTM globenewswire.com · about 20 hours ago

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product revenue from global sales of IMCIVREE of $71.3 million -- -- Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO (n=7) after 16 weeks of treatment -- -- Phase 3 TRANSCEND Trial Results in Acquired HO published in the New England Journal of Medicine -- -- Management to host conference call today at 8:00 a.m. ET --

BRK businesswire.com · about 20 hours ago

Bruker Reports Second Quarter 2026 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026. Frank H. Laukien, Bruker's President and CEO, commented: “We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year. Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter. In particular, we achieve.

RYM globenewswire.com · about 20 hours ago

RYTHM, Inc. Reports Second Quarter 2026 Results

ROLLING MEADOWS, Ill., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”), America's THC Company whose portfolio of trusted THC brands includes RYTHM, Señorita, incredibles, Beboe, and Dogwalkers, today announced financial results for the second quarter ended June 30, 2026.

ODTX globenewswire.com · about 20 hours ago

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase 2b monotherapy trial of OD-001 expected to initiate in 2H 2026 Cash on hand as of June 30, 2026 of $433.1M expected to fund operations into the second half of 2028 BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the second quarter ended June 30, 2026 and provided an update on recent progress and anticipated milestones. “Positive clinical proof-of-concept data for OD-001 marked an important milestone for Odyssey and we look forward to sharing additional, supportive data from this trial in October,” said Gary D.

← Newer
Older →